epidermal-growth-factor and perfluorooctane-sulfonic-acid

epidermal-growth-factor has been researched along with perfluorooctane-sulfonic-acid* in 1 studies

Other Studies

1 other study(ies) available for epidermal-growth-factor and perfluorooctane-sulfonic-acid

ArticleYear
PFOS disrupts key developmental pathways during hiPSC-derived cardiomyocyte differentiation in vitro.
    Toxicology in vitro : an international journal published in association with BIBRA, 2022, Volume: 85

    Exposure to perfluorooctanesulfonic acid (PFOS) has been associated with congenital heart disease (CHD) and decreased birth weight. PFOS exposure can disrupt signaling pathways relevant for cardiac development in stem cell-derived cardiomyocyte assays, such as the PluriBeat assay, where spheroids of human induced pluripotent stem cells (hiPSCs) differentiate into contracting cardiomyocytes. Notably, cell line origin can also affect how the assay responds to chemical exposure. Herein, we examined the effect of PFOS on cardiomyocyte differentiation by transcriptomics profiling of two different hiPSC lines to see if they exhibit a common pattern of disruption. Two stages of differentiation were investigated: the cardiac progenitor stage and the cardiomyocyte stage. Many differentially expressed genes (DEGs) were observed between cell lines independent of exposure. However, 135 DEGs were identified as common between the two cell lines. Of these, 10 DEGs were associated with GO-terms related to the heart. PFOS exposure disrupted multiple signaling pathways relevant to cardiac development, including WNT, TGF, HH, and EGF. Of these pathways, genes related to the non-canonical WNTCa

    Topics: Cell Differentiation; Epidermal Growth Factor; Humans; Induced Pluripotent Stem Cells; Myocytes, Cardiac

2022